Arcutis Biotherapeutics Inc
ARQT
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.17B
Close$
$-28.99
210.4% downside
Current Fair Value
210.4% downsideOvervalued by 210.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.17 Billion |
|---|---|
| Enterprise Value | $3.25 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.13 |
| Beta | 1.5 |
| Outstanding Shares | 130,522,000 |
Return
| Return on Equity | 12.93% |
|---|---|
| Return on Assets | 5.84% |
| Return on Invested Capital | 11.86% |
Valuation & Multiples
| P/E Ratio | 114.95 |
|---|---|
| PEG | -59.1 |
| Price to Sales | 8.76 |
| Price to Book Ratio | 26.27 |
| Enterprise Value to Revenue | 7.01 |
| Enterprise Value to EBIT | 83.61 |
| Enterprise Value to Net Income | 114 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.52 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$0.06
Average shareholder expectationRevenue Estimate
$118.85 M
Average shareholder expectationNext Earnings Call
Expected Date
October 27, 2026
EPS Estimate
$0.17
Average shareholder expectationRevenue Estimate
$141.69 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0842▼ 16.16% |
|---|---|
| Total Calls | 547,200▲ 63.44% |
| Total Puts | 46,100▼ 43.99% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 101.51%▼ 0.83% |
|---|---|
| Total Invested | $3.47B▲ 11.38% |
| Investors Holding | 282▲ 4.00% |
ESG Score
No data